1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

12 Apr 2024
Admin
News Article

Phanes Therapeutics' PT217 Receives Fast Track Designation from FDA

Overview

Phanes Therapeutics, Inc. (Phanes), a biotechnology company specializing in innovative oncology drug discovery and development, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PT217 for the treatment of patients with extensive-stage small cell lung cancer (ES-SCLC) who have experienced disease progression following platinum chemotherapy with or without a checkpoint inhibitor. PT217 was previously granted orphan drug designation for the treatment of small cell lung cancer by the FDA in 2022.

PT217

PT217 is a first-in-class native IgG-like bispecific antibody (bsAb) targeting DLL3 and CD47, and it is being developed for the treatment of patients with small cell lung cancer (SCLC), large cell neuroendocrine carcinoma of the lung (LCNEC), and extrapulmonary neuroendocrine carcinomas (EP-NECs).

SCLC

SCLC is a highly aggressive form of cancer characterized by high mortality rates and significant morbidities.
Patients diagnosed with ES-SCLC typically have an average survival duration of 2-4 months without treatment, which extends to 7-11 months with treatment.

Words from Phanes Therapeutics

Ming Wang, Founder and CEO of Phanes Therapeutics, expressed optimism about PT217's potential, stating, ""PT217 has the potential to be a transformative treatment option for patients with SCLC, LCNEC, and EP-NECs in various settings."" Wang also highlighted Phanes Therapeutics' recent achievement of securing two Fast Track designations, with PT886 receiving similar recognition last month for the treatment of metastatic claudin 18.2-positive pancreatic adenocarcinoma. Both assets are from Phanes' optimized anti-CD47 bispecific antibody franchise and are currently in clinical studies. Wang emphasized the belief in the potential of the optimized anti-CD47 bispecific antibody approach to unlock the full potential of the innate immunity in targeting solid tumors.

SKYBRIDGE Study

The multi-center Phase I clinical trial of PT217 (NCT05652686), known as the SKYBRIDGE study, is currently evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of PT217 in patients with advanced or refractory cancers expressing DLL3.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!